US FDA Reports Facial Paralysis In 4 Volunteers For Pfizer’s Covid-19 Vaccine

Mumbai : A new report by the United States Food and Drug Administration (FDA) regulators revealed that four volunteers for the COVID-19 experimental vaccine by Pfizer developed Bell’s Palsy after receiving vaccine shots, as per media reports.

Bell’s palsy is a condition that causes a temporary paralysis of the muscles in the face. It can occur when the nerve that controls your facial muscles becomes inflamed, swollen, or compressed.

FDA added in its report that it is unclear what caused Bell’s Palsy in the four volunteers. According to media reports, the FDA regulators have asked health experts to continuously monitor volunteers who had participated in the trials of the Covid-19 vaccine.

Earlier, Pfizer CEO Albert Bourla seemed dubious about the efficacy of the vaccine. During his interview with NBC’s Lestor Holt, he said, “I think this is something that needs to be examined. We are not certain about that right now with what we know.”

This comes as many countries, especially rich nations, are competing with each other to secure Covid-19 vaccines for their population. According to previous reports, some countries, including Canada, the US, UK, among others, have secured Covid-19 vaccines that are enough to inoculate their entire population multiple times, leaving lower-middle countries in a dearth of it.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’